The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study

N/ARecruitingNCT05874674

Wonju Severance Christian Hospital100 enrolled

Overview

Comparison nafamostat and low molecular weight heparin among dialysis patients

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

SINGLE

Enrollment

100

Conditions

Dialysis; Complications Bleeding

Interventions

Nafamostat MesylateDRUG

Comparison effect of nafamostat and cnoxan

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * platelet below 10k PTT above 60 second INR above 20 patient with bleeding (epistaxis, orbital bleeding, hematuria) recent brain hemorrhage (within 6 months) receiving anticoagulant therapy (coumadin or NOAC) dual antiplatelet agent users received major surgery within one month Exclusion Criteria: * cancer liver cirrhosis pregnancy drug allergy current bleeding on major organ (brain, gastrointestinal)

Locations (1)

Yonsei Unviersity Wonju College of Medicin

Wŏnju, Kangwondo, South Korea

RECRUITING

Outcomes

Primary Outcomes

Number of patients with severe bleeding

Brain hemorrhage (on brain CT), gastrointestinal bleeding (on EGD)

Time frame: 6 month

Secondary Outcomes

Number of patients with dialysis circuit clot

Dialysis circuit clotting due to not enough anticoagulation

Time frame: 6 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.